Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

LANTHEUS HOLDINGS, INC.

Parent2 subsidiariesUEI: XKLLNAJB6LJ6CAGE: 7ZG90

LANTHEUS HOLDINGS, INC. is a federal contractor, registered under UEI XKLLNAJB6LJ6 and CAGE code 7ZG90. It has been awarded $379,822 in federal contracts. Primary work spans Pharmaceutical Preparation Manufacturing. Top awarding agencies include Department Of Veterans Affairs.

Contact Information

Registration and classification details

Registration

UEI Code

XKLLNAJB6LJ6

CAGE Code

7ZG90

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationManufacturer of Goods

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Lanthue Holdings, Inc. operates as a specialized manufacturer within the pharmaceutical and medical chemical production sector, as indicated by its primary NAICS code 325412. The company focuses on the development and production of radiopharmaceuticals and other advanced therapeutic agents, leveragi...

Lanthue Holdings, Inc. operates as a specialized manufacturer within the pharmaceutical and medical chemical production sector, as indicated by its primary NAICS code 325412. The company focuses on the development and production of radiopharmaceuticals and other advanced therapeutic agents, leveraging precision chemistry, radiolabeling technologies, and GMP-compliant manufacturing processes. Its technical expertise includes the synthesis of complex molecular constructs, radioactive isotope handling, and closed-system aseptic processing to support diagnostic and therapeutic applications in nuclear medicine. The firm’s differentiation lies in its ability to scale small-batch, high-purity radiopharmaceutical production under stringent regulatory frameworks, ensuring consistency and safety for clinical use. No award history is available to infer specific agency relationships or contract patterns. Consequently, there is no demonstrable track record of direct engagement with federal agencies or government procurement programs based on the provided data. The company’s industry focus is centered on NAICS 325412, which encompasses the manufacturing of radiopharmaceuticals and other diagnostic imaging agents used in nuclear medicine. This vertical requires deep competency in radiochemistry, radiation safety, and FDA-regulated production protocols. Lanthue Holdings positions itself within the niche of advanced medical isotopes and targeted therapeutics, serving the clinical diagnostics and precision medicine markets through highly specialized manufacturing capabilities. As a 2L entity headquartered in North Billerica, Massachusetts, Lanthue Holdings, Inc. is structured as a small, technically focused manufacturer without public certifications. Its geographic presence is localized to its Massachusetts facility, suggesting a concentrated operational footprint aligned with biopharmaceutical innovation hubs in the Northeast. The company’s market positioning is defined by its technical specialization rather than broad government contracting experience.

Key Performance Metrics

Awards Count

3,775

All time

Active

43

Currently performing

Completed

3,727

Past period of performance

Total Awards

All time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with LANTHEUS HOLDINGS, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for LANTHEUS HOLDINGS, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in LANTHEUS HOLDINGS, INC.'s top NAICS codes and agencies

NAICS: 325412
New
DIBBS
HYDROXYPROPYL METHYLCE
Solicitation # SPE2DP-27-T-0185
Solicitation SPE2DP-27-T-0185 is a Small Business Set-Aside request for the procurement of Ocucoat Viscoelastic 1ML, a 2% hydroxypropyl methylcellulose ophthalmic solution (NSN 6505016331037). This FDA-regulated medical device is designed for high-volume, small-incision cataract surgery and lens inserter lubrication. The requirement consists of 5 boxes, with a delivery timeline of 79 days after receipt of order and an original required delivery date of October 27, 2026. Delivery is FOB Destination, with the final destination located at the USA Med Mat Ctr EUR in Kaiserslautern, Germany. The contract mandates strict quality and shelf-life compliance, requiring a non-extendable shelf life of 24 months per RS016. Packaging must be commercial and sealed to prevent damage, adhering to MIL-STD-2073-1E and DLA packaging requirements. Marking must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and must include the National Stock Number, manufacturer date, expiration or retest date, contract number, and lot number. Administrative requirements include the use of the Wide Area WorkFlow (WAWF) system for electronic invoicing and payment. The procurement is subject to various DFARS and FAR clauses, including the Buy American Act, safeguarding of covered defense information, and prohibitions on certain telecommunications equipment.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 22 hours ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
EMOLLIENT LOTION
Solicitation # SPE2DP-27-T-0188
Solicitation SPE2DP-27-T-0188 is a procurement for emollient lotion under NAICS code 325412, managed by the Defense Logistics Agency. The requirement consists of multiple line items, including 500 bottles for CLIN 0001 and 12 bottles for CLIN 0002, with an additional 250 bottles for CLIN 0003. The product must be a non-sterile, homogeneous oil-in-water or water-in-oil emulsion with a pH range between 5.0 and 8.1 and a viscosity of 10,000 to 20,000 CPS. Each unit consists of a 240 ML (8 FL OZ) bottle equipped with a dispenser cap. The lotion must contain water, a suitable oil, an emulsifier, and a preservative, and it must be stored at controlled room temperature. Delivery is required within 20 days after the order, with specific required delivery dates ranging from June 17, 2026, to July 20, 2026. Shipments are designated as FOB Destination to various locations, including the USS George Washington, USS Iwo Jima, and the USNS Mercy. Packaging must comply with MIL-STD-129 and Medical Marking Standard No. 1, with non-hazardous materials following ASTM D3951 and hazardous materials adhering to TQ requirement IP025 and FED-STD-313. Palletization must follow DLA requirement RP001. The contract incorporates various FAR and DFARS clauses, including the Buy American Act, Wide Area Workflow for electronic payments, and destination inspection requirements.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 22 hours ago

DEADLINE

in 5 days
View Details